Statement concerning the review of the approval of the active substance pirimicarb

On 26 August 2022, the European Commission asked EFSA to provide scientific and technical assistance according to Article 21(2) of Regulation (EC) No 1107/2009 concerning the review of the approval of the active substance pirimicarb and to deliver a statement on whether the applicable approval crite...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933487/
https://www.ncbi.nlm.nih.gov/pubmed/36818643
http://dx.doi.org/10.2903/j.efsa.2023.7807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933487/
https://www.ncbi.nlm.nih.gov/pubmed/36818643
http://dx.doi.org/10.2903/j.efsa.2023.7807

Ejemplares similares